Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 8/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23298235 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP3A4CYP2C9CCR5FKBP1A | |
| SCHEMBL23298255 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP3A4CYP2C9CCR5FKBP1A | |
| SCHEMBL23298258 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP3A4CYP2C9CCR5FKBP1A | |
| SCHEMBL23298237 | 1.00 | CYP2C19 (0.43) | CYP2C19CYP3A4CYP2C9CCR5FKBP1A | |
| SCHEMBL23342998 | 0.88 | USP30 (0.48) | CYP2C19CYP3A4CYP2C9FKBP1A | |
| SCHEMBL28838656 | 0.88 | USP30 (0.48) | CYP2C19CYP3A4CYP2C9FKBP1A | |
| SCHEMBL28838706 | 0.88 | USP30 (0.48) | CYP2C19CYP3A4CYP2C9FKBP1A | |
| SCHEMBL23342997 | 0.88 | USP30 (0.48) | CYP2C19CYP3A4CYP2C9FKBP1A | |
| SCHEMBL23343010 | 0.88 | USP30 (0.48) | CYP2C19CYP3A4CYP2C9FKBP1A | |
| SCHEMBL29542437 | 0.86 | CCR5 (0.43) | CYP2C19CYP3A4CYP2C9CCR5FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4334325-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220396589-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-12-15 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396589-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP2C19 3891/4885CYP3A4 3727/4885CYP2C9 3894/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CYP2C19 2980/4885CYP3A4 3310/4885CYP2C9 3287/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP2C19 3930/4885CYP3A4 3780/4885CYP2C9 3961/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CYP2C19 4869/4885CYP3A4 4873/4885CYP2C9 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.